Filtros de búsqueda

Lista de obras de Michele Maio

"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.

artículo científico publicado en 2016

"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.

artículo científico publicado en 2015

5-AZA-2'-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story

scientific article published on 01 March 2007

5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?

artículo científico publicado en 2003

A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients

article by Lorenzo Pilla et al published 8 October 2005 in Cancer Immunology, Immunotherapy

A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

artículo científico publicado en 2014

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

artículo científico publicado en 2008

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

scientific article published on 01 June 1997

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy

scientific article published on 18 December 2018

Adjuncts in diagnosis, prognosis, and clinical monitoring of breast, gynecologic, and hematolymphopoietic malignancies: Third Joint International Workshop, Lacco Ameno d'Ischia, Italy, October 2001.

artículo científico publicado en 2002

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

artículo científico

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial

scientific article published on 07 August 2019

Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.

artículo científico publicado en 2003

Anti-CTLA-4 antibody adjuvant therapy in melanoma

artículo científico publicado en 2010

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models

artículo científico publicado en 2015

BIPHASIC CONTROL OF NF-κB ACTIVATION INDUCED BY THE TRIGGERING OF HLA-DR ANTIGENS EXPRESSED ON B CELLS

scientific article published on 01 May 1997

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

artículo científico publicado en 2016

Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

artículo científico publicado en 2016

Biology and clinical applications of CD40 in cancer treatment

scientific article published on October 2010

Biomarkers for immune checkpoint inhibitors – Authors' reply

artículo científico publicado en 2014

Biomolecular strategies for therapeutic intervention in cancer

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy

artículo científico publicado en 2010

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

artículo científico publicado en 2010

CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?

artículo científico publicado en 2014

CXCR6, a newly defined biomarker of tissue-specific stem cell asymmetric self-renewal, identifies more aggressive human melanoma cancer stem cells.

artículo científico publicado en 2010

Cancer classification using the Immunoscore: a worldwide task force

artículo científico publicado en 2012

Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention

artículo científico publicado en 2009

Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications

artículo científico publicado en 2002

Cancer therapies: basic and clinical perspectives in brain, prostate, and lung tumors: Naples, September, 24-27, 2000.

artículo científico publicado en 2001

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

artículo científico publicado en 2016

Circulating CD4+ T cells that produce IL4 or IL17 when stimulated by melan-A but not by NY-ESO-1 have negative impacts on survival of patients with stage IV melanoma

artículo científico publicado en 2014

Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study

artículo científico publicado en 2022

Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes

artículo científico publicado en 2012

Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme.

artículo científico publicado en 2013

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

artículo científico publicado en 2014

Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications.

scientific article published on October 2010

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

artículo científico publicado en 2014

Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis.

artículo científico publicado en 2008

Defining the critical hurdles in cancer immunotherapy

artículo científico publicado en 2011

Diagnostic and therapeutic approaches in Italian hospitals: adjuvant and metastatic therapy in melanoma.

artículo científico publicado en 2013

Differential levels of soluble endoglin (CD105) in myeloid malignancies

artículo científico publicado en 2003

Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions

artículo científico publicado en 1999

Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells

artículo científico publicado en 1989

Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.

artículo científico publicado en 2014

Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).

artículo científico publicado en 2012

Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response

artículo científico publicado en 2013

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.

artículo científico publicado en 2015

Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

artículo científico publicado en 2014

Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma

artículo científico publicado en 2013

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.

artículo científico publicado en 2010

Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010.

artículo científico publicado en 2011

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology

artículo científico publicado en 2009

Emerging role of endoglin (CD105) as a marker of angiogenesis with clinical potential in human malignancies.

artículo científico publicado en 2003

Endoglin (CD105): a target for anti-angiogenetic cancer therapy

artículo científico publicado en 2003

Epigenetic drugs as immunomodulators for combination therapies in solid tumors

artículo científico

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

artículo científico publicado en 2007

Epigenetic immunomodulation of hematopoietic malignancies.

artículo científico publicado en 2005

Epigenetic markers of prognosis in melanoma

artículo científico publicado en 2014

Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications

artículo científico publicado en 2012

Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.

artículo científico publicado en 2010

Epigenetics meets immune checkpoints.

artículo científico

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

artículo científico publicado en 2010

Epigenetics of melanoma: implications for immune-based therapies.

artículo científico

Erratum: anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.

artículo científico publicado en 2015

European approach to antibody-based immunotherapy of melanoma.

artículo científico publicado en 2002

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Expression and functional role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on human blood cells

artículo científico publicado en 1992

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

artículo científico publicado en 2011

Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial

artículo científico publicado en 2015

Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis

artículo científico publicado en 2012

Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications.

artículo científico publicado en 2007

Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010"

artículo científico publicado en 2011

Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".

artículo científico publicado en 2012

Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.

artículo científico publicado en 2014

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma

scientific article published on 01 March 2019

Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT).

artículo científico publicado en 2017

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

artículo científico publicado en 2009

HLA and prognostic factors in primary breast cancer.

artículo científico publicado en 1985

Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Heat shock proteins and their use as anticancer vaccines.

artículo científico publicado en 2004

Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer.

artículo científico publicado en 2003

Heterogeneity in the mitogenic response of peripheral blood mononuclear cells to a pan T monoclonal antibody

artículo científico publicado en 1988

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma

artículo científico publicado en 2013

High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients

artículo científico publicado en 2009

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

artículo científico publicado en 2004

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.

artículo científico publicado en 2016

Immune checkpoint blockade in malignant mesothelioma

artículo científico

Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

artículo científico publicado en 2014

Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies

artículo científico

Immunologic Checkpoints for Cancer Treatment: A Continuing Success

scientific article published on 12 February 2015

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

artículo científico publicado en 2015

Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide.

artículo científico publicado en 2012

Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts

artículo científico publicado en 2018

Immunotherapy of brain metastases: breaking a "dogma"

scientific article published on 17 October 2019

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

artículo científico publicado en 2011

In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells

artículo científico publicado en 1999

Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy

artículo científico publicado en 2015

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

artículo científico publicado en 2018

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study

artículo científico publicado en 2015

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine.

artículo científico publicado en 2004

Introduction: Melanoma: American and European perspectives on diagnosis and treatment

artículo científico publicado en 2002

Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

artículo científico publicado en 2017

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

artículo científico publicado en 2012

Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).

artículo científico publicado en 2010

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.

artículo científico publicado en 2011

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

artículo científico publicado en 2011

Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy

artículo científico publicado en 2014

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

artículo científico publicado en 2014

Is it the primetime for endoglin (CD105) in the clinical setting?

artículo científico publicado en 2006

Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma

artículo científico publicado en 2010

Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides

artículo científico publicado en 2012

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

artículo científico publicado en 2013

Longitudinal study of recurrent metastatic melanoma cell lines underscores the individuality of cancer biology.

artículo científico publicado en 2013

MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE

artículo científico publicado en 1984

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma as a model tumour for immuno-oncology ⬇️

artículo científico publicado el 1 de septiembre de 2012

Melanoma immunotherapy: new dreams or solid hopes?

scientific article published on 01 September 1996

Melanoma-associated hypopigmentation: where are the antibodies?

artículo científico publicado en 1996

Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment

artículo científico publicado en 2000

Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients

artículo científico publicado en 2011

Methylation-regulated expression of HLA class I antigens in melanoma

artículo científico publicado en 2003

Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implications.

artículo científico publicado en 2005

Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10.

artículo científico publicado en 1989

Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy

artículo científico publicado en 2015

Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer

artículo científico publicado en 2020

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

artículo científico publicado en 2013

New dimensions in cancer biology and therapy

scientific article published on 01 May 2000

Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19-22, 2011: New perspectives in the immunotherapy of cancer

artículo científico publicado en 2012

Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma

article

Nivolumab in previously untreated melanoma without BRAF mutation

artículo científico publicado en 2015

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

artículo científico publicado en 2015

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

artículo científico publicado en 2004

Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement

scientific article published on 01 December 2000

Peptide-based vaccines for cancer therapy

artículo científico publicado en 2014

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients

artículo científico publicado en 2017

Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy

artículo científico publicado en 2020

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

artículo científico publicado en 2013

Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications

artículo científico publicado en 2006

Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab

artículo científico publicado en 2017

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

artículo científico publicado en 2016

Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.

artículo científico publicado en 2002

Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells.

artículo científico publicado en 2002

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

artículo científico publicado en 2011

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

artículo científico publicado en 2014

Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma

artículo científico publicado en 2013

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program

artículo científico publicado en 2014

Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, 1-3 October 2009.

artículo científico publicado en 2010

Signaling by HLA class II antigens on B cells

article

Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16-18 October 2008.

artículo científico publicado en 2009

Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

artículo científico publicado en 2017

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?

artículo científico publicado en 2011

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.

artículo científico publicado en 2014

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours

artículo científico publicado en 2009

Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma

artículo científico publicado en 2004

Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012.

artículo científico publicado en 2013

The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy

article

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.

artículo científico publicado en 2008

The biology of cancer testis antigens: putative function, regulation and therapeutic potential

artículo científico publicado en 2011

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

artículo científico publicado en 2006

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

artículo científico publicado en 2010

The ipilimumab lesson in melanoma: achieving long-term survival

artículo científico

The role of BRAF V600 mutation in melanoma

artículo científico publicado en 2012

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

artículo científico publicado en 2009

Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study

artículo científico publicado en 2014

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond.

artículo científico

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours

artículo científico publicado en 2014

Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study).

artículo científico publicado en 2012

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

artículo científico publicado en 2013

Update on the role of ipilimumab in melanoma and first data on new combination therapies

artículo científico publicado en 2013

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

artículo científico publicado en 2002

Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells

artículo científico publicado en 1999

Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells

artículo científico publicado en 2001

Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.

artículo científico publicado en 2015

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

artículo científico publicado en 2016

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

article published in 2015

“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013

article

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda